Table V. Comparison of demographic and clinical characteristics of AD1 and AD2 subgroups.
| Variable | AD1 (n = 24) | AD2 (n = 31) | p |
|---|---|---|---|
| Age (S.D.), years | 85.0 (7.1) | 83.8 (7.1) | 0.56 |
| Male | 9 (37.5%) | 19 (61.3%) | 0.08 |
| PMI (S.D.), hours | 5.5 (2.6) | 6.9 (3.9) | 0.11 |
| Age of onseta (S.D.), years | 76.9 (6.9) | 75.4 (7.3) | 0.46 |
| Duration of illnessa (S.D.), years | 7.8 (3.1) | 8.4 (3.6) | 0.53 |
| Last MMSE (S.D.) | 15.3 (5.9) | 15.1 (6.3) | 0.87 |
| Psychosis | 8 (33.3%) | 12 (38.7%) | 0.68 |
| Lewy body stage | 0.86 | ||
| Negative | 13 (54.2%) | 16 (51.6%) | |
| Brainstem/transitional | 7 (29.2%) | 8 (25.8%) | |
| Neocortical | 4 (16.7%) | 7 (22.6%) | |
| CERAD plaque score of frequent | |||
| MFa | 22 (95.7%) | 28 (90.3%) | 0.46 |
| ERC | 23 (95.8%) | 28 (90.3%) | 0.16 |
| CERAD NFT score of frequent | |||
| MF | 11 (42.3%) | 15 (57.7%) | 0.39 |
| ERC | 23 (95.8%) | 30 (96.8%) | 0.85 |
| Braak stage | 0.30 | ||
| III | 1 (4.2%) | 5 (16.1%) | |
| IV | 10 (41.7%) | 9 (29.0%) | |
| V | 13 (54.2%) | 17 (54.8%) | |
| APOE genotype | 0.03b | ||
| 23 | 0 (0%) | 1 (3.2%) | |
| 24 | 0 (0%) | 2 (6.5%) | |
| 33 | 8 (33.3%) | 19 (61.3%) | |
| 34 | 14 (58.3%) | 8 (25.8%) | |
| 44 | 2 (8.3%) | 1 (3.2%) |
PMI—postmortem interval; MMSE—MiniMental State Exam; CERAD—Consortium to Establish a Registry for Alzheimer's Disease; NFT—neurofibrillary tangle.
a n = 54 for this variable.
b Fisher's exact test for the distribution of genotypes. For the comparison of APOE*4 carriers versus noncarriers, p = 0.02.